Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Baxter
McKinsey
Johnson and Johnson
Mallinckrodt
Dow

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Tegafur-uracil

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Tegafur-uracil?

Tegafur-uracil is an investigational drug.

There have been 79 clinical trials for Tegafur-uracil. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.

The most common disease conditions in clinical trials are Stomach Neoplasms, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Taiho Oncology, Inc., and Fudan University.

There are four hundred and twenty-seven US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for Tegafur-uracil
TitleSponsorPhase
Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic CancerFudan UniversityPhase 2
SOX-based CRT for Esophageal Cancer.Zhejiang Provincial People’s HospitalPhase 1/Phase 2
Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLCThe First Affiliated Hospital with Nanjing Medical UniversityPhase 3

See all Tegafur-uracil clinical trials

Clinical Trial Summary for Tegafur-uracil

Top disease conditions for Tegafur-uracil
Top clinical trial sponsors for Tegafur-uracil

See all Tegafur-uracil clinical trials

US Patents for Tegafur-uracil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tegafur-uracil   Start Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Start Trial
Tegafur-uracil   Start Trial Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Tegafur-uracil   Start Trial Molecular constructs with targeting and effector moieties   Start Trial
Tegafur-uracil   Start Trial Glutaminase inhibitors and method of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tegafur-uracil

Drugname Country Document Number Estimated Expiration Related US Patent
Tegafur-uracil World Intellectual Property Organization (WIPO) 2015148714 2034-03-25   Start Trial
Tegafur-uracil Australia 2015231053 2034-03-21   Start Trial
Tegafur-uracil Brazil 112016021620 2034-03-21   Start Trial
Tegafur-uracil Canada 2943339 2034-03-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
McKesson
Medtronic
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.